Although the molecular mechanisms by which Aβ and NFTs affect synaptic and cognitive function have yet to be fully elucidated (Nam et al., 2019), drugs that inhibit and/or prevent the accumulation of Aβ and hyperphosphorylation of tau may be useful for target‐based treatment of AD. Here, MAPT is linked to Alzheimer disease.